Collectionner le produit
Détails du produit
Materials Provided
IDComponentsSizeA006-214Human LDL R35 μgA007-214Biotinylated Human PCSK910 μgA003-214Streptavidin-HRP10 μgPC9-NA003Anti-PCSK9 Neutralizing Antibody40 μgProduct Overview
PCSK9 [Biotinylated] : LDL R Inhibitor Screening ELISA Assay Pair is based on a competition-ELISA method, is used to screening for inhibitors of human PCSK9 binding to human LDL R. The kit is designed to provide a reliable solution for the screening of antibodies and small molecule inhibitors in the early stages, as well as QC release, to help researchers quickly screen and validate drugs, effectively improving research and development efficiency. It can also be used as a universal detection tool to identify the ability of human PCSK9 to bind to human LDL R.
Reconstitution
See Certificate of Analysis for details of reconstitution instruction and specific concentration.
Storage
1. Unopened kit should be stored at -25~-15℃ upon receiving.
2. Find the expiration date on the outside packaging and do not use reagents past their expiration date.
3. The opened kit should be stored per components table. The shelf life is 30 days from the date of opening.
ACRO Quality Management System
Les clients ont également consulté
Affichage des données
Typical Data
Please refer to DS document for the assay protocol.
INHIBITION OF PCSK9 [BIOTINYLATED]: LDL R BINDING BY ANTI-PCSK9 NEUTRALIZING ANTIBODY
Serial dilutions of anti-PCSK9 neutralizing antibody (Catalog # PC9-NA003) (1:2 serial dilutions, from 20 μg/mL to 0.04 μg/mL or 133.33 nM to 0.26 nM) were added into Biotinylated PCSK9: LDL R binding reactions. Background was subtracted from data points prior to log transformation and curve fitting (QC tested).
Avis des utilisateurs Publier un commentaire
Progrès de frontière
Progrès du développement médicamenteux- Nom anglais：
Proprotein convertase subtilisin kexin type 9
- Catégorie：
- Nombre de médicaments répertoriés：
8 Détails
- Nombre de médicaments cliniques：
35 Détails
- Étape de développement la plus élevée：
Approved
Contact Us
Drug Candidate Licensing
